Eisai Inc. Assumes U.S. Distribution Responsibilities for Aciphex(R); Company Accomplishes Long-Term Goal for Aricept(R) and Aciphex(R).

Publication: PR Newswire

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2004 PR Newswire Association LLC

TEANECK, N.J., Jan. 7 /PRNewswire/ -- Eisai Inc. announced today that the company has assumed the U.S. distribution responsibilities for Aciphex(R) (rabeprazole sodium) from Janssen Pharmaceutica, Inc. affiliate JOM Pharmaceutical Services. Eisai and Janssen will continue to co-promote Aciphex(R), a proton pump inhibitor (PPI) prescribed for gastroesophageal reflux disease (GERD), in the United States. The partnership with Janssen for sales, marketing and further clinical development remains unchanged for the duration of the co-promotion agreement.

Effective December 29, 2003, Eisai is fulfilling purchase orders for Aciphex(R) from a contract distribution center in Memphis, Tenn. Aciphex(R) was discovered and developed by Eisai and is manufactured and packaged in its Research Triangle Park, N.C., facility.

"The transition of the distribution of Aciphex(R) to Eisai marks the accomplishment of an important long-term goal...

Read the full article for free courtesy of your local library.